KalVista Shares Positive Phase 3 Trial Results of EKTERLY for Children with Hereditary Angioedema

KalVista Pharmaceuticals presented positive interim Phase 3 results from the KONFIDENT-KID trial for EKTERLY (sebetralstat), used in children ages 2-11 with hereditary angioedema (HAE), at the 2026 Global Angioedema Leadership Conference. These results suggest EKTERLY may provide effective on-demand treatment for pediatric HAE attacks. 

KalVista Pharmaceuticals, Inc. announced new interim results from its KONFIDENT-KID clinical trial evaluating EKTERLY (sebetralstat) for the on-demand treatment of hereditary angioedema (HAE) attacks in children ages 2-11 presented at the 2026 Global Angioedema Leadership Conference. 

It is designed to enable compliance with treatment guidelines, consistent with the recently published “International Guideline on the Diagnosis and Management of Pediatric Patients with Hereditary Angioedema,” which recommends ensuring on-demand treatment is available anytime, anywhere, and prioritises early intervention and rapid self-administration, regardless of attack severity or location. 

According to Towards Healthcare, the hereditary angioedema therapeutics market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 5.89 billion in 2026 to approximately USD 12.55 billion by 2035, representing a compound annual growth rate (CAGR) of 8.76% from 2026 to 2035. Towards Healthcare projects, the hereditary angioedema therapeutics market will grow significantly from 2026 to 2035. Growth is expected due to increased diagnosis rates, enhancements in diagnostics, and innovations in drug delivery that support patient convenience and adherence. 

Ben Palleiko, Chief Executive Officer of KalVista, said that each update from KONFIDENT-KID continues to build compelling evidence that sebetralstat has the potential to transform the treatment paradigm for children living with HAE. The broader sebetralstat program remains efficient, safe, and consistent, which includes rapid symptom relief  

About Hereditary Angioedema 

It is a rare genetic disease resulting in a deficiency of the C1 esterase inhibitor (C1INH) protein and subsequent uncontrolled activation of the kallikrein-kinin system. People living with HAE experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected.  

Treatment recommends treating attacks as early as possible to prevent progression of swelling and shorten the time to attack resolution, and to consider treatment for all attacks, regardless of anatomic location or severity. 

A recent report by Towards Healthcare highlights that the Hereditary angioedema therapeutics market is witnessing a rise in the prevalence of HAE reporting across developed and emerging regions, creating sustained demand for effective therapies and gene-targeted approaches is expanding the treatment landscape. 

North America has retained early-mover advantages in access and reimbursement, with a focus on innovative therapies and treatment options that improve patient outcomes and adherence. Asia-Pacific is the fastest-growing region, driven by improving awareness, healthcare infrastructure, and the use of prophylactic and targeted therapies.